Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • CTSU E1910
  • This study in being done to determine what affects (good and bad) the therapy blinatumomab has on your type of cancer (BCR/ABL negative Acute Lymphoblastic Leukemia). This new therapy will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinotumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.

  • CTSU EA9131
  • Acute Promyelocytic Leukemia is a highly curable leukemia with most large clinical trials showing a survival above 90%. These trials are conducted in experienced centers on a protocol. However, APL is an uncommon disease and doctors who are not routinely involved in taking care of APL patients in smaller centers as well as in larger treatment centers, may not be familiar with the treatment or expected complications. In recent years, results from several centers and countries showed that 1 in 3 (30%) patients diagnosed with APL die within the first month of diagnosis from complications. These deaths are most often from bleeding, infections, and complications from drugs. It may be possible to prevent many of these deaths if these complications are prevented, recognized early and treated aggressively.  The patients who survived the first month had an excellent quality of life with a low chance of relapse and treatment related complications.

     

    We developed a set of simple guidelines based on recommendations from experts and used them in a preliminary trial that resulted in a marked decrease in early deaths.  The guidelines when used with advice from APL experts by phone or email decreases complications and deaths further.

    The purpose of this study is to see if implementing our APL guidelines along with support from APL experts will decrease deaths and improve survival. In addition data will be collected from patient medical records and maintained on a database. This information will help us understand if the guidelines have been followed and the effect on preventing complications and death. It will also allow us to learn more about APL treatment, based on the care you received.

    The goal is to decrease early deaths by using the guidelines we developed as well as your doctor communicating with experts who have more experience in treating APL.

  • CTSU ECOG-ACRIN EAI141
  • SWOG S1318
  • The purpose of this study is to test any good and bad effects of adding the drug blinatumomab to different doses of standard combination of chemotherapy drugs.  This will help to determine if these standard therapy drugs can be given at lower doses (when given with blinatumomab) in order to reduce overall side effects and be effective in treating ALL.  The addition of blinatumomab, an investigational drug, to usual treatment could help get rid of the leukemia cells and help keep them from coming back, but it could also cause side effects.  Researchers hope to learn if the addition of the study drug will keep the leukemia cells from coming back for a longer period of time than usual treatment alone.  One of the other drugs being used, dasatinib, has been approved for other types of leukemia, but is investigational for this study.